As part of my academic program, I am working on a research paper that explores the advantages and disadvantages of protected cell captives (PCCs) in the insurance industry. During my extensive research on the topic, I have encountered challenges in finding up-to-date information regarding Solvency requirements in relation with Protected Cell Companies. As Malta allows the establishment of PCCs under its insurance legislation, there needs to be a regulatory framework. Considering the importance of Solvency II in the insurance sector and its potential impact on PCCs, I would greatly appreciate it if you could provide me with any recent information, guidelines, or documents pertaining to the intersection of PCCs and Solvency II. It would be particularly helpful to receive any materials that reflect the current regulatory framework and any specific considerations or requirements that apply to PCCs under Solvency II.